David M. Nanus

1987–2025 年に発表

116
論文数
25,907
被引用数
77
h 指数
115
i10 指数

被引用数

David M. Nanus の年別被引用数1991 年: 被引用 2 件1992 年: 被引用 2 件1993 年: 被引用 16 件1994 年: 被引用 16 件1995 年: 被引用 22 件1996 年: 被引用 21 件1997 年: 被引用 32 件1998 年: 被引用 40 件1999 年: 被引用 60 件2000 年: 被引用 63 件2001 年: 被引用 50 件2002 年: 被引用 62 件2003 年: 被引用 57 件2004 年: 被引用 92 件2005 年: 被引用 83 件2006 年: 被引用 81 件2007 年: 被引用 82 件2008 年: 被引用 83 件2009 年: 被引用 86 件2010 年: 被引用 89 件2011 年: 被引用 113 件2012 年: 被引用 122 件2013 年: 被引用 153 件2014 年: 被引用 198 件2015 年: 被引用 185 件2016 年: 被引用 289 件2017 年: 被引用 336 件2018 年: 被引用 403 件2019 年: 被引用 967 件2020 年: 被引用 1,107 件2021 年: 被引用 1,215 件2022 年: 被引用 872 件2023 年: 被引用 590 件2024 年: 被引用 1,035 件2025 年: 被引用 413 件2026 年: 被引用 7 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,377 件、この内訳の 31%中国: 引用元論文 888 件、この内訳の 8.2%イギリス: 引用元論文 681 件、この内訳の 6.2%ドイツ: 引用元論文 589 件、この内訳の 5.4%カナダ: 引用元論文 574 件、この内訳の 5.3%イタリア: 引用元論文 552 件、この内訳の 5.1%フランス: 引用元論文 384 件、この内訳の 3.5%オーストラリア: 引用元論文 347 件、この内訳の 3.2%日本: 引用元論文 318 件、この内訳の 2.9%スペイン: 引用元論文 305 件、この内訳の 2.8%オランダ: 引用元論文 291 件、この内訳の 2.7%スイス: 引用元論文 274 件、この内訳の 2.5%
0%31%その他 21.2%

分野

  • Medicine69.9%
  • Biochemistry, Genetics and Molecular Biology23.5%
  • Immunology and Microbiology2.3%
  • Engineering1.7%
  • Neuroscience0.8%
  • Materials Science0.5%
  • その他1.3%

トピック

  • Prostate Cancer Treatment and Research14.9%
  • Prostate Cancer Diagnosis and Treatment5.9%
  • Radiopharmaceutical Chemistry and Applications4.8%
  • Cancer Genomics and Diagnostics4.1%
  • Cancer Cells and Metastasis2.5%
  • Renal cell carcinoma treatment2.4%
  • その他65.4%

共著者

全論文

検索で開く
  1. Integrative Clinical Genomics of Advanced Prostate Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Victor E. Reuter, Anuradha Gopalan, Jianjiong Gao, Massimo Loda, Rosina T. Lis, Michaela Bowden, Stephen Balk, Glenn C. Gaviola, Carrie Sougnez, Manaswi Gupta, Evan Y. Yu, Elahe A. Mostaghel, Heather H. Cheng, Hyojeong Mulcahy, Lawrence D. True, Stephen R. Plymate, Heidi Dvinge, Roberta Ferraldeschi, Penny Flohr, Susana Miranda, Zafeiris Zafeiriou, Nina Tunariu, Joaquı́n Mateo, Raquel Pérez-López, Francesca Demichelis, Brian D. Robinson, Marc Schiffman, David M. Nanus, Scott T. Tagawa, Alexandros Sigaras, Kenneth Eng, Olivier Elemento, Andrea Sboner, Elisabeth I. Heath, Howard I. Scher, Kenneth J. Pienta, Philip W. Kantoff, Johann S. de Bono, Mark A. Rubin, Peter S. Nelson, Levi A. Garraway, Charles L. Sawyers, Arul M. Chinnaiyan - Cell 2015 被引用: 3,701

  2. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer

    著者: , , , , , , , , , , , , , , , , , , - Nature Medicine 2016 被引用: 1,729

  3. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Peter S. Nelson, Lawrence H. Schwartz, Susan Halabi, Philip W. Kantoff, Andrew J. Armstrong - Journal of Clinical Oncology 2016 被引用: 1,603

  4. Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2011 被引用: 1,020

  5. Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Science Translational Medicine 2019 被引用: 209

  6. Patient derived organoids to model rare prostate cancer phenotypes

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Francesca Demichelis, Mark A. Rubin, Himisha Beltran - Nature Communications 2018 被引用: 356

  7. Clinical features of neuroendocrine prostate cancer

    著者: , , , , , , , , , , , , , - European Journal of Cancer 2019 被引用: 363

  8. Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 被引用: 364

  9. A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2018 被引用: 275

  10. Integrative Clinical Genomics of Advanced Prostate Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Victor E. Reuter, Anuradha Gopalan, Jianjiong Gao, Massimo Loda, Rosina T. Lis, Michaela Bowden, Stephen Balk, Glenn C. Gaviola, Carrie Sougnez, Manaswi Gupta, Evan Y. Yu, Elahe A. Mostaghel, Heather H. Cheng, Hyojeong Mulcahy, Lawrence D. True, Stephen R. Plymate, Heidi Dvinge, Roberta Ferraldeschi, Penny Flohr, Susana Miranda, Zafeiris Zafeiriou, Nina Tunariu, Joaquı́n Mateo, Raquel Pérez-López, Francesca Demichelis, Brian D. Robinson, Andrea Sboner, Marc Schiffman, David M. Nanus, Scott T. Tagawa, Alexandros Sigaras, Kenneth Eng, Olivier Elemento, Andrea Sboner, Elisabeth I. Heath, Howard I. Scher, Kenneth J. Pienta, Philip W. Kantoff, Johann S. de Bono, Mark A. Rubin, Peter S. Nelson, Levi A. Garraway, Charles L. Sawyers, Arul M. Chinnaiyan - Cell 2015 被引用: 591

  11. Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer

    著者: , , , , , , , , , , , , , , , , , , - Journal of Clinical Investigation 2020 被引用: 192

  12. A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer

    著者: , , , , , , , , , , , , , , - Clinical Cancer Research 2020 被引用: 129

  13. Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer

    著者: , , , , , , , , , , , , , , , , , , , - Nature Communications 2021 被引用: 88

  14. Prostate-Specific Membrane Antigen–Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591

    著者: , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 被引用: 67

  15. Phase II Study of Lutetium-177–Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer

    著者: , , , , , , , , , , , , - Clinical Cancer Research 2013 被引用: 426

  16. Concurrent AURKA and MYCN Gene Amplifications Are Harbingers of Lethal TreatmentRelated Neuroendocrine Prostate Cancer

    著者: , , , , , , , , , , , , - Neoplasia 2013 被引用: 249

  17. Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2019 被引用: 212

  18. Phase I Trial of 177Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer

    著者: , , , , , - Journal of Clinical Oncology 2005 被引用: 508

  19. Trastuzumab, Paclitaxel, Carboplatin, and Gemcitabine in Advanced Human Epidermal Growth Factor Receptor-2/ neu –Positive Urothelial Carcinoma: Results of a Multicenter Phase II National Cancer Institute Trial

    著者: , , , , , , , , , , , - Journal of Clinical Oncology 2007 被引用: 374

  20. Clonal evolution of chemotherapy-resistant urothelial carcinoma

    著者: , , , , , , , , , , , , , - Nature Genetics 2016 被引用: 301

  21. Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity

    著者: , , , , , , , , , , , , , - European Urology 2012 被引用: 457

  22. Phase 1/2 study of fractionated dose lutetium‐177–labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 ( 177 Lu‐J591) for metastatic castration‐resistant prostate cancer

    著者: , , , , , , , , , , , - Cancer 2019 被引用: 133

  23. SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy

    著者: , , , , , , , , , , , , , , , - Molecular Cancer Therapeutics 2020 被引用: 71

  24. Renal-Cell Carcinoma

    著者: , , - New England Journal of Medicine 1996 被引用: 2,248